gamma-aminobutyric acid has been researched along with Cancer of Head in 8 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 9.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "This pilot study is the first prospective randomized trial of gabapentin for RIM-related pain." | 9.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "Development of "burning"-type oral dysesthesia occurred in patients treated with the combination of gefitinib, paclitaxel, and external beam radiation of the oral tongue." | 9.13 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "To report a high incidence of oral mucosal dysesthesia occurring in patients on a pilot study of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa) in combination with paclitaxel (Taxol) and external beam radiation therapy for the treatment of locally advanced squamous cell carcinoma of the head and neck." | 9.13 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM." | 8.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "No systematic reviews exist on the role of gabapentin for neuropathic pain in radiation-induced OM." | 8.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "At a median dose of 2700 mg/day of gabapentin, only 33% and 55% of patients required additional low-dose narcotic medications for pain control during the third and fourth week of treatment, respectively, despite exhibiting a grade 2 or higher mucositis in 71% and 86% of the patients, respectively." | 7.76 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "This retrospective study evaluated the efficacy of gabapentin for the treatment of pain syndromes related to radiation-induced mucositis in patients with head and neck cancers treated with concurrent chemoradiation." | 7.76 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "Gabapentin appears promising in reducing the need for narcotic pain medication for patients with head and neck malignancies treated with IMRT and should be further evaluated prospectively in controlled clinical trials." | 7.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "By using a median dose of 2700 mg/day of gabapentin, only 10% of patients required additional narcotic pain medications for adequate pain relief during the third and fourth week of treatment, despite grade 2 or higher mucositis present in 56% and 73% of the patients, respectively." | 7.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors." | 7.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "Gabapentin was maintained at 900mg/day for 4 weeks after CRT." | 6.82 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "Development of "burning"-type oral dysesthesia occurred in patients treated with the combination of gefitinib, paclitaxel, and external beam radiation of the oral tongue." | 6.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "Gabapentin (Neurontin) was administered to 2 patients as a treatment for painful mucosal neuropathy." | 6.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "All had stage III/IVA-B squamous cell carcinoma of the head and neck." | 6.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "This dysesthesia was improved by the use of gabapentin." | 6.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "The patients without grade 3 oral dysesthesia received less than 50 Gy radiation to the oral tongue." | 6.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "The oral dysesthesia was exacerbated by the ingestion of neutral pH liquids such as water." | 6.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "Prophylactic gabapentin appears to be a promising treatment option for preventing pain, reducing opioids, and reducing weight loss in patients undergoing head and neck cancer therapy." | 5.41 | Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis. ( Murphy, BA; Smith, DK; Smith, LE, 2023) |
| "Gabapentin was initiated in the second week of radiotherapy." | 5.36 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "This pilot study is the first prospective randomized trial of gabapentin for RIM-related pain." | 5.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 5.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "To report a high incidence of oral mucosal dysesthesia occurring in patients on a pilot study of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa) in combination with paclitaxel (Taxol) and external beam radiation therapy for the treatment of locally advanced squamous cell carcinoma of the head and neck." | 5.13 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "Development of "burning"-type oral dysesthesia occurred in patients treated with the combination of gefitinib, paclitaxel, and external beam radiation of the oral tongue." | 5.13 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "No systematic reviews exist on the role of gabapentin for neuropathic pain in radiation-induced OM." | 4.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM." | 4.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors." | 3.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "By using a median dose of 2700 mg/day of gabapentin, only 10% of patients required additional narcotic pain medications for adequate pain relief during the third and fourth week of treatment, despite grade 2 or higher mucositis present in 56% and 73% of the patients, respectively." | 3.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "Gabapentin appears promising in reducing the need for narcotic pain medication for patients with head and neck malignancies treated with IMRT and should be further evaluated prospectively in controlled clinical trials." | 3.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "This retrospective study evaluated the efficacy of gabapentin for the treatment of pain syndromes related to radiation-induced mucositis in patients with head and neck cancers treated with concurrent chemoradiation." | 3.76 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "At a median dose of 2700 mg/day of gabapentin, only 33% and 55% of patients required additional low-dose narcotic medications for pain control during the third and fourth week of treatment, respectively, despite exhibiting a grade 2 or higher mucositis in 71% and 86% of the patients, respectively." | 3.76 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "Gabapentin was maintained at 900mg/day for 4 weeks after CRT." | 2.82 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "Development of "burning"-type oral dysesthesia occurred in patients treated with the combination of gefitinib, paclitaxel, and external beam radiation of the oral tongue." | 2.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "This dysesthesia was improved by the use of gabapentin." | 2.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "The patients without grade 3 oral dysesthesia received less than 50 Gy radiation to the oral tongue." | 2.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "All had stage III/IVA-B squamous cell carcinoma of the head and neck." | 2.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "Gabapentin (Neurontin) was administered to 2 patients as a treatment for painful mucosal neuropathy." | 2.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "The oral dysesthesia was exacerbated by the ingestion of neutral pH liquids such as water." | 2.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "Gabapentin was initiated in the second week of radiotherapy." | 1.36 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Smith, LE | 1 |
| Murphy, BA | 1 |
| Smith, DK | 1 |
| Yang, W | 1 |
| McNutt, TR | 1 |
| Dudley, SA | 1 |
| Kumar, R | 1 |
| Starmer, HM | 1 |
| Gourin, CG | 1 |
| Moore, JA | 1 |
| Evans, K | 1 |
| Allen, M | 1 |
| Agrawal, N | 1 |
| Richmon, JD | 1 |
| Chung, CH | 1 |
| Quon, H | 3 |
| Kataoka, T | 1 |
| Kiyota, N | 1 |
| Shimada, T | 1 |
| Funakoshi, Y | 1 |
| Chayahara, N | 1 |
| Toyoda, M | 1 |
| Fujiwara, Y | 1 |
| Nibu, K | 1 |
| Komori, T | 1 |
| Sasaki, R | 1 |
| Mukohara, T | 1 |
| Minami, H | 1 |
| Sanders, JG | 1 |
| Dawes, PJ | 1 |
| Milazzo-Kiedaisch, CA | 1 |
| Itano, J | 1 |
| Dutta, PR | 3 |
| Sharp, H | 1 |
| Morris, JC | 1 |
| Van Waes, C | 1 |
| Gius, D | 1 |
| Cooley-Zgela, T | 1 |
| Singh, AK | 1 |
| Bar Ad, V | 2 |
| Weinstein, G | 2 |
| Chalian, A | 2 |
| Both, S | 2 |
| Dosoretz, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized Double Blind Trial to Assess the Effect of a Single Preoperative Dose of Gabapentin on Postoperative Opioid Consumption in Patients Undergoing Rhinoplasty[NCT03498261] | Phase 1 | 50 participants (Actual) | Interventional | 2018-01-30 | Active, not recruiting | ||
| Efficacy of Preoperative Administration of Gabapentin in Managing Intraoperative and Postoperative Pain From Third Molar Extractions.[NCT04860141] | Phase 4 | 98 participants (Anticipated) | Interventional | 2021-06-16 | Recruiting | ||
| Effect of Gabapentin on Postoperative Opioid Analgesic Use and Pain in Adolescents Undergoing Tonsillectomy[NCT05024825] | Phase 4 | 17 participants (Actual) | Interventional | 2017-08-04 | Terminated (stopped due to recruitment target not met.) | ||
| A Pilot Phase I Dose Escalation Study Of The EGFR Tyrosine Kinase Inhibitor Gefitinib (Iressa) Combined With Paclitaxel (Taxol) And External Beam Radiation Therapy In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck (SCCHN)[NCT00083057] | Phase 1 | 30 participants (Anticipated) | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for gamma-aminobutyric acid and Cancer of Head
| Article | Year |
|---|---|
Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis.
Topics: Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric | 2023 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2016 |
2 trials available for gamma-aminobutyric acid and Cancer of Head
| Article | Year |
|---|---|
Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer.
Topics: Acetaminophen; Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Carcinoma | 2016 |
High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers.
Topics: Adult; Aged; Amines; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2008 |
3 other studies available for gamma-aminobutyric acid and Cancer of Head